This may provide an explanation for its upregulation seen in NASH and NAFLD that may happen in addition to SREBP-mediated transcriptional induction of caspase-2 [41], as these diseases are characterized by loss of functional parenchyma and compensatory proliferation [58]. Here, CASP2 is linked to metabolic dysfunction-associated steatotic liver disease.